These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16808060)

  • 21. Cetuximab-induced pneumonitis in head and neck cancer patient.
    De Vos FY; Driessen CM; Jaspers HC; van Herpen CM; Simons B
    Oral Oncol; 2012 Jun; 48(6):e17-8. PubMed ID: 22342570
    [No Abstract]   [Full Text] [Related]  

  • 22. Expanding the Reach of Anti-PD-1 Therapy.
    Cancer Discov; 2015 Jul; 5(7):684-5. PubMed ID: 26034052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma.
    Chung CH; Pohlmann PR; Rothenberg ML; Burkey BB; Parker J; Palka K; Aulino J; Puzanov I; Murphy B
    Head Neck; 2011 Dec; 33(12):1804-8. PubMed ID: 20652976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of advanced head and neck cancer with cetuximab.
    Merlano M; Garrone O
    Int J Biol Markers; 2007; 22(1 Suppl 4):S71-6. PubMed ID: 17520584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cetuximab (erbitux).
    Bou-Assaly W; Mukherji S
    AJNR Am J Neuroradiol; 2010 Apr; 31(4):626-7. PubMed ID: 20167650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
    Herbst RS; Hong WK
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
    Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
    Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs.
    Blasco MA; Svider PF; Raza SN; Jacobs JR; Folbe AJ; Saraf P; Eloy JA; Baredes S; Fribley AM
    Laryngoscope; 2017 Nov; 127(11):2565-2569. PubMed ID: 28581126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Manageable early toxicity of cetuximab concurrent with radical radiotherapy for locally advanced head and neck cancer.
    Wieczorek A; Hamid A; O'Toole L
    Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):496. PubMed ID: 21482459
    [No Abstract]   [Full Text] [Related]  

  • 30. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
    Herbst RS; Langer CJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biotech firm faces challenges from FDA, falling stock prices.
    Reynolds T
    J Natl Cancer Inst; 2002 Mar; 94(5):326-8. PubMed ID: 11880468
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
    Eder J; Simonitsch-Klupp I; Trautinger F
    Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Short-term efficacy of cetuximab combined with radiotherapy or chemotherapy on head and neck cancer: a report of 11 cases].
    Xia LP; Zhang B; Liu MZ; Hu PL; Chen XX; Guo GF; Qiu HJ; Rong YM; Qian SY; Zhou FF; Huang YY; Wang TL
    Ai Zheng; 2009 Sep; 28(9):977-82. PubMed ID: 19728918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cetuximab and the Head and Neck Squamous Cell Cancer.
    Concu R; Cordeiro MNDS
    Curr Top Med Chem; 2018; 18(3):192-198. PubMed ID: 29332581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in head and neck squamous cell carcinoma--a review.
    Safdari Y; Khalili M; Farajnia S; Asgharzadeh M; Yazdani Y; Sadeghi M
    Clin Biochem; 2014 Sep; 47(13-14):1195-202. PubMed ID: 24912050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?
    Alorabi M; Shonka NA; Ganti AK
    Crit Rev Oncol Hematol; 2016 Mar; 99():170-9. PubMed ID: 26797287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erbitux trial flawed from the beginning, committee finds.
    Randal J
    J Natl Cancer Inst; 2002 Dec; 94(24):1824-5. PubMed ID: 12488469
    [No Abstract]   [Full Text] [Related]  

  • 38. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
    Song Q; Li X; Li B
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
    Machiels JP; Schmitz S
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are anti-vitamin K drugs contraindicated with cetuximab during head-and-neck cancer concomitant radiotherapy?
    Brohée D; Henry AR; Castadot P
    Acta Clin Belg; 2013; 68(3):237-9. PubMed ID: 24156231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.